Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ENOCHIAN BIOSCIENCES, INC.

(ENOB)
SummaryQuotesChartsNewsCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Enochian Biosciences : Says FDA Accepted its Pre-Investigational New Drug Request for Potential Hepatitis B Drug

07/12/2021 | 07:20am EDT


© MT Newswires 2021
All news about ENOCHIAN BIOSCIENCES, INC.
10:54aENOCHIAN BIOSCIENCES : Announces Its Successful Completion of FDA Pre-IND for a Potential ..
PU
08:40aENOCHIAN BIOSCIENCES : Says Pre-Investigational New Drug Process Completed for Proposed He..
MT
07:00aENOCHIAN BIOSCIENCES : Announces Its Successful Completion of FDA Pre-IND for a Potential ..
AQ
09/24ENOCHIAN BIOSCIENCES : Management's Discussion and Analysis of Financial Condition and Res..
AQ
09/24Enochian Biosciences, Inc. Reports Earnings Results for the Full Year Ended June 30, 20..
CI
09/22NORTH AMERICAN MORNING BRIEFING : Stock Futures -2-
DJ
09/13ENOCHIAN BIOSCIENCES INC : Regulation FD Disclosure, Financial Statements and Exhibits (fo..
AQ
09/13ENOCHIAN BIOSCIENCES : Slide Presentation Here
PU
09/13ENOCHIAN BIOSCIENCES : to Present to Investors at the H.C. Wainwright 23rd Annual Investme..
AQ
08/30ENOCHIAN BIOSCIENCES : Distinguished Scientific and Public Health Leaders to Join Enochian..
PU
More news
Financials (USD)
Sales 2021 - - -
Net income 2021 -26,7 M - -
Net cash 2021 13,3 M - -
P/E ratio 2021 -8,77x
Yield 2021 -
Capitalization 399 M 399 M -
EV / Sales 2020 -
EV / Sales 2021 -
Nbr of Employees 11
Free-Float 38,2%
Chart ENOCHIAN BIOSCIENCES, INC.
Duration : Period :
Enochian Biosciences, Inc. Technical Analysis Chart | ENOB | US29350E1047 | MarketScreener
Technical analysis trends ENOCHIAN BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Managers and Directors
Mark Richard Dybul Executive Vice Chairman & Chief Executive Officer
Luisa Puche Chief Financial Officer
Rene Sindlev Chairman
Joseph R. Cohen Director-Research & Discovery
Carl Sandler Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ENOCHIAN BIOSCIENCES, INC.149.49%384
GILEAD SCIENCES, INC.22.19%89 259
BIONTECH SE309.08%80 542
REGENERON PHARMACEUTICALS32.25%66 425
WUXI APPTEC CO., LTD.35.04%59 817
VERTEX PHARMACEUTICALS-22.31%47 634